Navigation Links
Drug Candidates in Pipeline Offer Potential for Parkinson's Disease Therapeutics Market, Says Frost & Sullivan

LONDON, Dec. 9 /PRNewswire/ -- The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief. With the introduction of newer dopamine agonists as well as fresh recommendations and treatment guidelines that call for using dopamine agonists as first-line therapy, the market is experiencing a shift away from the use of carbidopa/levodopa.


New analysis from Frost & Sullivan (, European Markets for Parkinson's Disease Therapeutics, finds that the market earned revenues of over $1.28 billion in 2008 and estimates this to reach $2.28 billion in 2015.

"Although prescriptions for Sinemet and Sinemet controlled release (CR) continue to be written to a large extent, dopamine agonists prescriptions are increasing as well," says Frost & Sullivan Programme manager Paljit Sohal. "Other drugs account for a relatively small portion of the total prescriptions, while some, such as the catechol-o-methyltransferase (COMT) inhibitors are directly linked with Sinemet prescriptions."

The introduction of Mirapex and Requip has been largely responsible for driving the market over the recent period. The increased use of these medications is spurred by the recent announcements from key physician groups recommending their use in early-stage Parkinson's disease and calling for delay in the use of carbidopa/levodopa due to concerns over the development of clinically relevant dyskinesias.

However, there are considerable chances for physicians to misdiagnose Parkinson's disease. The number of cases that go undiagnosed or misdiagnosed each year range from approximately 20.0 per cent to 40.0 per cent of the total cases. In most cases, the disease is not diagnosed until 80 per cent of the dopamine-producing neurotransmitters are depleted. Earlier diagnosis and treatment has the potential to greatly improve prognosis.

"An estimated one million patients are afflicted with the disease and as many as 4,00,000 are improperly diagnosed or under-diagnosed," explains Ms. Sohal. "Recognising the early signs of the disease and making a referral to a neurologist represent the potential for the disease to go undiagnosed."

Biomarkers and imaging techniques are likely to improve the diagnosis of the condition at a much earlier stage and hence, their development should be supported. High-risk individuals must be identified prior to clinical onset of the disease and disease progression along with response to various therapies should be monitored.

"Market participants should collaborate with neurologists and physicians to improve the rate and the process of diagnosis," concludes Ms. Sohal. "This will expand the target population and thereby, market revenues."

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an e-mail to Katja Feick, Corporate Communications, at, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country. Upon receipt of the above information, a brochure will be sent to you by e-mail.

European Markets for Parkinson's Disease Therapeutics is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Biosimilars Market Outlook, Eastern Drug Delivery Markets - Opportunity Analysis, and European Lung Cancer Therapeutics Markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit

European Markets for Parkinson's Disease Therapeutics (M32D)

Katja Feick
Corporate Communications - Europe
P: +49 (0) 69 7703343

SOURCE Frost & Sullivan

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Tetraphase Pharmaceuticals Completes Series B Financing to Support the Advancement of Novel Antibiotic Drug Candidates
2. Cognition Therapeutics Closes Series A Financing to Advance Drug Candidates for Alzheimers Disease
3. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
4. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
7. Leading AIDS Groups Turn Up The Heat on 08 Presidential Candidates
8. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
9. Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
10. Amgen Recognized for Best Pipeline and Best New Drug at Scrip Awards
11. Reportlinker Adds Ion Channel Modulator Pipelines: Targets and Agents in Development
Post Your Comments:
(Date:10/9/2015)... DIEGO , Oct. 9, 2015 Ansun ... (Infectious Disease Society of America ) regarding the compassionate ... transplant patient on a respirator who was co-infected with ... a five-day course of therapy, O 2 requirement ... the patient was able to go off the respirator ...
(Date:10/8/2015)... October 9, 2015 ® ... diagnostic colonoscopy. The NOCT study also assessed the ... --> ® ) in adult patients ... study also assessed the compliance, safety, patient acceptability ... today announced positive top line results for its ...
(Date:10/8/2015)... PITTSBURGH , Oct. 8, 2015 /PRNewswire/ ... pharmaceutical company, will host a conference call and webcast ... ET to review the value to be created for ... TASE) through Mylan,s offer to acquire the company. During ... outlines the compelling proposition for Perrigo shareholders. Mylan,s offer ...
Breaking Medicine Technology:
... IDEV Technologies, Inc. (IDEV) today announced the firm ... Australia,s regulatory agency for medical drugs and devices, for ... and peripheral procedures. "We are pleased to ... SUPERA VERITAS in the Australian market later this year," ...
... 28, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the ... Paris, France. "The data we are ... an important new treatment option for patients with multiple ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... A new health tool that helps identify if a ... ( ) – just in time for the cold and flu season, which ... for many in the U.S., the real start of cold/flu season is the start ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington Beach ... system that uses clear, plastic aligners. This alternative to braces has become wildly ... allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, so ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... The Asthma ... the US Centers for Disease Control and Prevention (CDC) to improve the knowledge and ... that AAFA has been awarded a project by the CDC and allows AAFA to ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... individuals from all walks of life to save money on the high cost ... $25 per month per medication, individuals and families can receive their medications delivered ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan Fox, ... largest recreational dispensaries in Colorado, says the latest figures on the state’s sales ... maturing into a legitimate industry. , Last month, according to the ...
Breaking Medicine News(10 mins):
... ... Integration project team including Drummond Group Inc., the trusted interoperability test lab, to conduct a ... project and leading the testing efforts with strong support from the project stakeholders. ... Austin, TX (PRWEB) December 7, ...
... ... medical research. , ... AZ (PRWEB) December 7, 2009 -- is doing its part to help find a ... Cure Catheters to its list of nearly 45,000 products., , ,Cure Medical is a forward-thinking ...
... , NEW ORLEANS, Dec. 7 ... Ruth Pettengell, M.D. of St. George,s Hospital, University of London during ... Meeting updated results from the pivotal phase III EXTEND (PIX 301) ... or refractory, aggressive non-Hodgkin,s lymphoma ("NHL") patients who have failed ...
... , OAK BROOK, Ill., Dec. ... academic medical center (AMC) members for their achievements in ... 10 organizations are noted for modeling best practices in ... ) , The winners were determined using 2008 ...
... the loss of a key segment of DNA can lead to ... this kind of genetic alteration can cause obesity. The results are ... Dr Sadaf Farooqi from the University of Cambridge and Dr Matt ... with severe obesity. The team scanned each child,s entire genome ...
... Dec. 6 Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... 003-A1 study, known as the 003 trial, demonstrating that carfilzomib ... patients. These data were presented today at the ASH/ASCO Joint ... of Hematology (ASH) in New Orleans. Enrollment in this trial ...
Cached Medicine News:
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Eliminating the need for any manual pipetting, the HydraPLUS delivers precise micro-volumes of sample directly from primary tubes to four HYDRASYS sample applicators contained in a built-in humidity ...
Handheld Digital Retinal Camera...
Medicine Products: